Pharmacotherapy for behavioral symptoms of frontotemporal dementia

Pharmacotherapy for behavioral symptoms of frontotemporal dementia - Pharmacotherapy for frontotemporal dementia

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002704

Enrollment

Registered

2009-11-04

Start date

2008-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

frontotemporal dementia

Interventions

dose of 7.5 g/day Yokukansan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: FTD patients diagnosed according to Consensus guidelines of FTD (Neurology 1998; 51: 1546-1554)

Exclusion criteria

Exclusion criteria: (1) delirium due to metabolic intoxication and drug use; (2) alcoholism, stroke, depression, manic state, and schizophrenia before the onset of FTD; (3) previous use of Yokukansan, major tranquilizers, and antidepressants; (4) neoplastic disease and acute inflammation

Design outcomes

Primary

Measure	Time frame
Neuropsychiatric Inventory (NPI)	—

Secondary

Measure	Time frame
Stereotypy Rating Inventory (SRI)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026